Literature DB >> 31515024

Novel inverse planning optimization algorithm for robotic radiosurgery: First clinical implementation and dosimetric evaluation.

Michele Zeverino1, Maud Marguet1, Cedric Zulliger2, André Durham2, Raphael Jumeau2, Fernanda Herrera2, Luis Schiappacasse2, Jean Bourhis2, Francois O Bochud1, Raphael Moeckli3.   

Abstract

PURPOSE: A novel optimization algorithm (VOLO™) for robotic radiosurgery in the Precision™ treatment planning system was evaluated for different SRS/SBRT treatments and compared with the previous Sequential Optimization (SO) algorithm.
MATERIALS AND METHODS: Fifty cases of brain, spine, prostate and lung tumors previously optimized with SO, were re-planned with VOLO™ algorithm keeping the same prescription, collimator type and size, optimization shells, and blocking structures. The dosimetric comparison involved target coverage, conformity (CI), gradient (GI) and homogeneity indexes, specific indicators of dose to OARs and number of nodes, beams, MU and delivery time. For brain only, plans were IRIS- and MLC-based (10 each). The remaining 30 plans were all IRIS-based.
RESULTS: VOLO™ optimization was significantly superior for target coverage for prostate and spine, CI for brain, and for brain and urethra dose sparing. SO gave significantly better results for GI for prostate. VOLO™ showed a significantly steeper dose fall-off for brain MLC-based, while for prostate and spine SO was superior. For IRIS-based plans, VOLO™ significantly reduced the nodes (36%), beams (14%), and MU (31%). This led to an average reduction of delivery time of 20% (from 8% for brain to 30% for prostate). For MLC-based plans, VOLO™ significantly increased the nodes and beams (42%) keeping the same number of MU. The averaged delivery time increased by 18%.
CONCLUSIONS: With respect to SO, VOLO™ optimization algorithm provided better results in terms of delivery time for IRIS-based and of quality of dose distribution for MLC-based plans, respectively.
Copyright © 2019 Associazione Italiana di Fisica Medica. Published by Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Cyberknife; Inverse planning; Plan comparison; SBRT; SRS

Mesh:

Year:  2019        PMID: 31515024     DOI: 10.1016/j.ejmp.2019.07.020

Source DB:  PubMed          Journal:  Phys Med        ISSN: 1120-1797            Impact factor:   2.685


  5 in total

1.  Largely reduced OAR doses, and planning and delivery times for challenging robotic SBRT cases, obtained with a novel optimizer.

Authors:  Marta K Giżyńska; Linda Rossi; Wilhelm den Toom; Maaike T W Milder; Kim C de Vries; Joost Nuyttens; Ben J M Heijmen
Journal:  J Appl Clin Med Phys       Date:  2021-01-21       Impact factor: 2.102

2.  Impact of prescription isodose level and collimator selection on dose homogeneity and plan quality in robotic radiosurgery.

Authors:  Alexandra Hellerbach; Markus Eichner; Daniel Rueß; Klaus Luyken; Mauritius Hoevels; Michael Judge; Christian Baues; Maximilian Ruge; Martin Kocher; Harald Treuer
Journal:  Strahlenther Onkol       Date:  2021-12-09       Impact factor: 4.033

3.  Applying pytorch toolkit to plan optimization for circular cone based robotic radiotherapy.

Authors:  Bin Liang; Ran Wei; Jianghu Zhang; Yongbao Li; Tao Yang; Shouping Xu; Ke Zhang; Wenlong Xia; Bin Guo; Bo Liu; Fugen Zhou; Qiuwen Wu; Jianrong Dai
Journal:  Radiat Oncol       Date:  2022-04-20       Impact factor: 4.309

4.  Technical feasibility of online adaptive stereotactic treatments in the abdomen on a robotic radiosurgery system.

Authors:  Maaike T W Milder; Alba Magallon-Baro; Wilhelm den Toom; Erik de Klerck; Lorne Luthart; Joost J Nuyttens; Mischa S Hoogeman
Journal:  Phys Imaging Radiat Oncol       Date:  2022-07-28

5.  Implementing and evaluating a high-resolution diode array for patient-specific quality assurance of robotic brain stereotactic radiosurgery/radiotherapy.

Authors:  Qianyi Xu; Kiet Huynh; Wei Nie; Mark S Rose; Ashish K Chawla; Kevin S Choe; Samir Kanani; Gregory J Kubicek; Jiajin Fan
Journal:  J Appl Clin Med Phys       Date:  2022-03-12       Impact factor: 2.243

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.